Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Niina Laurila"'
Autor:
Niina Laurila, Katri Pylkäs, Katrin Rapakko, Thomas W. P. Friedl, Hellevi Peltoketo, Heli Nevanlinna, Muthiah Bose, Robert Winqvist, Hanna Tuppurainen, Jonas Willmann, Lisa Wiesmüller, Kerstin Borgmann, Ann Christin Parplys, Helmut Pospiech, Felix Meyer, Juliane Sachsenweger, Lisa Heiserich, Johannes Jungwirth, Pentti Nieminen, Marco Groth
Publikováno v:
Human Molecular Genetics.
Whilst heterozygous germline mutations in the ABRAXAS1 gene have been associated with a hereditary predisposition to breast cancer, their effect on promoting tumourigenesis at the cellular level has not been explored. Here, we demonstrate in patient-
Autor:
Raman Devarajan, Hellevi Peltoketo, Tuomo Mantere, Niina Laurila, Susanna Koivuluoma, Anna Tervasmäki, Hanna Tuppurainen, Leila Eshraghi, Katri Pylkäs, Veli-Pekka Ronkainen
Publikováno v:
International Journal of Cancer
Strong inherited predisposition to breast cancer is estimated to cause about 5–10% of all breast cancer cases. As the known susceptibility genes, such as BRCA1 and BRCA2, explain only a fraction of this, additional predisposing genes and related bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17277b7b0aafad0610115ebbafbb79d0
http://urn.fi/urn:nbn:fi-fe2019093030494
http://urn.fi/urn:nbn:fi-fe2019093030494
Autor:
Bing Xia, Kerstin Borgmann, Katri Pylkäs, Helmut Pospiech, Melissa C. Southey, Felix Meyer, Robert Winqvist, William D. Foulkes, Niina Laurila, Muthiah Bose
Publikováno v:
Cancer Research. 80:2335-2335
During the last decade, PALB2 has been defined as a high-risk breast cancer susceptibility gene alongside BRCA1 and BRCA2. Heterozygous mutation in PALB2 increases the lifetime breast cancer risk of female carriers to an average of 53%, but the risk
Publikováno v:
Oncotarget
Treatment resistance significantly inhibits the efficiency of targeted cancer therapies in drug-sensitive genotypes. In the current work, we studied mechanisms for rapidly occurring, adaptive resistance in targeted therapy-sensitive lung, breast, and
Autor:
Lisa Wiesmüller, Hellevi Peltoketo, Thomas W. Dunlop, Jonas Willmann, Ganapathy Raman Devarajan, Lisa Heiserich, Hanna Tuppurainen, Robert Winqvist, Katri Pylkas, Pentti Nieminen, Kerstin Borgmann, Niina Laurila, Marco Groth, Felix Meyer, Muthiah Bose, Leila Eshraghi, Katrin Rapakko, Thomas Wolfram Paul Friedl, Juliane Sachsenweger, Helmut Pospiech, Ann Christin Parplys, Heli Nevanlinna
Publikováno v:
Cancer Research. 78:339-339
Whilst heterozygous germline mutations in the ABRAXAS gene have been associated with hereditary breast cancer predisposition, their initial effect on promoting tumorigenesis at the cellular level has not been explored. Here, we demonstrate in patient
EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models
Autor:
Jussi Koivunen, Niina Laurila
Publikováno v:
Medical Oncology. 32
Acquired resistance to EGFR TKIs is the most important limiting factor for treatment efficiency in EGFR-mutant NSCLC. Although the continuation of EGFR TKI beyond disease progression in combination with chemotherapy is often suggested as a strategy f
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 612 (2012)
BMC Cancer
BMC Cancer
Background PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways are thought to be the central transducers of oncogenic signals in solid malignancies, and there has been a lot of enthusiasm for developing inhibitors of these pathways for cancer therapy. Some pr